Abstract
Evaluation Of Direct Cost Of Adverse Drug Reactions To Highly Active Antiretroviral Therapy In Indian Human Immunodeficiency Virus Positive Patients
Highlights
Human immunodeficiency virus (HIV) infected patients requires a combination of three to four antiretroviral, termed highly active antiretroviral therapy (HAART)
HIV-infected hospitalized in-patients of either sex who were on fixed dose drug combinations of HAART were included in the study and HIV positive patients with Systemic Lupus Erythmatosus (SLE), cancer, pregnant women and patients with traditional medicines were excluded from the study
A total of 110 HIV positive patients (84 males and 26 females) with HAART were admitted to the hospital during the study period
Summary
Human immunodeficiency virus (HIV) infected patients requires a combination of three to four antiretroviral, termed highly active antiretroviral therapy (HAART). According to NACO treatment, HIV infected patients receive a fixed dose HAART regimen, consisting of either zidovudine or stavudine with lamivudine in combination with either efavirenz or nevirapine.[5] In India, 25% of HIV patients discontinue their initial HAART regimen within the first eight months of therapy because of ADRs which leads to noncompliance.[6] Studies[7,8,9,10] have assessed the direct cost of ADRs at different hospitals using length of stay as a parameter for evaluation. Thiyagu et al[2] study from India showed that total cost incurred due to ADRs in a tertiary care teaching hospital was found to be US$ 36451 with average US$ 115 per patient hospitalized with ADRs. The aim of this work was to evaluate the direct cost incurred in the management of ADRs to HAART in Indian HIV positive patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
